Tags

Type your tag names separated by a space and hit enter

Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
Am J Med Genet B Neuropsychiatr Genet. 2016 12; 171(8):1131-1138.AJ

Abstract

Mild cognitive impairment (MCI) is the transition stage between the normal aging process and dementia itself. The most common clinical phenotype is amnestic MCI (aMCI) [subtypes: single domain (sMCI) and multiple domains (mMCI)], which is considered prodromal to Alzheimer's disease (AD). The APOE (apolipoprotein E) e4 allele is the most important genetic risk factor for AD, but its association with MCI onset and conversion to AD is controversial. In this follow-up study of 88 aMCI patients (68% sMCI and 32% mMCI at baseline), we examined APOE genotypes and plasma levels in relation to MCI development and progression based on their clinical/cognitive data obtained at baseline and follow-up assessment (mean follow-up time = 6.6 ± 3.4 years). A control sample (n = 164) was collected in previous investigations. The overall conversion rate to mMCI or AD was 52.2%. The APOE e4 allele was associated with a higher risk of developing MCI (OR: 2.23; 95%CI: 1.22-4.08). The conversion rate in the e4 allele carriers (32% of the sample) was 71%, and the e4 allele was associated with a higher risk of conversion to mMCI/AD (OR: 4.1; 95%CI: 1.2-13.6). APOE e2 allele carriers were 7% (all sMCI) and none progressed to mMCI/AD. Among MCI subjects, e4 carriers had the lowest plasma apoE levels (37.8 ± 12.5 mg/L), and e2 carriers had the highest (78.6 ± 38.1 mg/L). APOE e4 is a risk allele for the development and progression of aMCI, the APOE e2 allele seems to be protective, and apoE levels associated to them are an integral part of their action. © 2016 Wiley Periodicals, Inc.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Scarabino D
CNR Institute of Cellular Biology and Neurobiology, Monterotondo Scalo, Rome, Italy.
Broggio E
Alzheimer's Disease Center, Department of Neuroscience, University and Hospital of Verona, Verona, Italy.
Gambina G
Alzheimer's Disease Center, Department of Neuroscience, University and Hospital of Verona, Verona, Italy.
Maida C
S. Giovanni Addolorata Hospital, Rome, Italy.
Gaudio MR
S. Giovanni Addolorata Hospital, Rome, Italy.
Corbo RM
Department of Biology and Biotechnology, La Sapienza University, Rome, Italy. CNR Institute of Molecular Biology and Pathology, Rome, Italy.

MeSH

AgedAged, 80 and overAllelesAlzheimer DiseaseApolipoproteins ECognition DisordersCognitive DysfunctionDementiaDisease ProgressionFemaleFollow-Up StudiesGene FrequencyGenetic Predisposition to DiseaseGenotypeHeterozygoteHumansMaleNeuropsychological TestsRisk Factors

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27604972

Citation

Scarabino, Daniela, et al. "Apolipoprotein E Genotypes and Plasma Levels in Mild Cognitive Impairment Conversion to Alzheimer's Disease: a Follow-up Study." American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, vol. 171, no. 8, 2016, pp. 1131-1138.
Scarabino D, Broggio E, Gambina G, et al. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study. Am J Med Genet B Neuropsychiatr Genet. 2016;171(8):1131-1138.
Scarabino, D., Broggio, E., Gambina, G., Maida, C., Gaudio, M. R., & Corbo, R. M. (2016). Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, 171(8), 1131-1138. https://doi.org/10.1002/ajmg.b.32495
Scarabino D, et al. Apolipoprotein E Genotypes and Plasma Levels in Mild Cognitive Impairment Conversion to Alzheimer's Disease: a Follow-up Study. Am J Med Genet B Neuropsychiatr Genet. 2016;171(8):1131-1138. PubMed PMID: 27604972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study. AU - Scarabino,Daniela, AU - Broggio,Elisabetta, AU - Gambina,Giuseppe, AU - Maida,Carlotta, AU - Gaudio,Maria Rosa, AU - Corbo,Rosa Maria, Y1 - 2016/09/08/ PY - 2016/03/11/received PY - 2016/08/18/accepted PY - 2016/9/9/pubmed PY - 2017/9/22/medline PY - 2016/9/9/entrez KW - APOE genotypes KW - Alzheimer's disease KW - mild cognitive impairment KW - plasma APOE levels SP - 1131 EP - 1138 JF - American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics JO - Am J Med Genet B Neuropsychiatr Genet VL - 171 IS - 8 N2 - Mild cognitive impairment (MCI) is the transition stage between the normal aging process and dementia itself. The most common clinical phenotype is amnestic MCI (aMCI) [subtypes: single domain (sMCI) and multiple domains (mMCI)], which is considered prodromal to Alzheimer's disease (AD). The APOE (apolipoprotein E) e4 allele is the most important genetic risk factor for AD, but its association with MCI onset and conversion to AD is controversial. In this follow-up study of 88 aMCI patients (68% sMCI and 32% mMCI at baseline), we examined APOE genotypes and plasma levels in relation to MCI development and progression based on their clinical/cognitive data obtained at baseline and follow-up assessment (mean follow-up time = 6.6 ± 3.4 years). A control sample (n = 164) was collected in previous investigations. The overall conversion rate to mMCI or AD was 52.2%. The APOE e4 allele was associated with a higher risk of developing MCI (OR: 2.23; 95%CI: 1.22-4.08). The conversion rate in the e4 allele carriers (32% of the sample) was 71%, and the e4 allele was associated with a higher risk of conversion to mMCI/AD (OR: 4.1; 95%CI: 1.2-13.6). APOE e2 allele carriers were 7% (all sMCI) and none progressed to mMCI/AD. Among MCI subjects, e4 carriers had the lowest plasma apoE levels (37.8 ± 12.5 mg/L), and e2 carriers had the highest (78.6 ± 38.1 mg/L). APOE e4 is a risk allele for the development and progression of aMCI, the APOE e2 allele seems to be protective, and apoE levels associated to them are an integral part of their action. © 2016 Wiley Periodicals, Inc. SN - 1552-485X UR - https://www.unboundmedicine.com/medline/citation/27604972/Apolipoprotein_E_genotypes_and_plasma_levels_in_mild_cognitive_impairment_conversion_to_Alzheimer's_disease:_A_follow_up_study_ DB - PRIME DP - Unbound Medicine ER -